Which has preferable valuation & earnings, BEAT or CCLD?

CareCloud has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartBeam N/A N/A -$21.01M -$0.56 N/A CareCloud $120.50M 0.78 $10.80M $0.11 20.18

Is BEAT or CCLD more profitable?

CareCloud has a net margin of 7.87% compared to HeartBeam's net margin of 0.00%. CareCloud's return on equity of 24.05% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,034.04% -434.40% CareCloud 7.87% 24.05% 16.38%

Is BEAT or ZEPP more profitable?

HeartBeam has a net margin of 0.00% compared to Zepp Health's net margin of -14.70%. Zepp Health's return on equity of -15.64% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -1,034.04% -434.40% Zepp Health -14.70% -15.64% -6.03%

Does the media refer more to BEAT or ZEPP?

In the previous week, HeartBeam and HeartBeam both had 2 articles in the media. HeartBeam's average media sentiment score of 0.50 beat Zepp Health's score of 0.27 indicating that HeartBeam is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zepp Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OM or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Outset Medical's net margin of -63.65%. Outset Medical's return on equity of -56.13% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Outset Medical -63.65% -56.13% -27.45% HeartBeam N/A -1,034.04% -434.40%

Does the media prefer OM or BEAT?

In the previous week, Outset Medical had 2 more articles in the media than HeartBeam. MarketBeat recorded 4 mentions for Outset Medical and 2 mentions for HeartBeam. Outset Medical's average media sentiment score of 1.60 beat HeartBeam's score of 0.50 indicating that Outset Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Outset Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PIII or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%. P3 Health Partners' return on equity of 0.00% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -8.57% N/A -19.99% HeartBeam N/A -1,034.04% -434.40%

Does the media prefer PIII or BEAT?

In the previous week, P3 Health Partners and P3 Health Partners both had 2 articles in the media. HeartBeam's average media sentiment score of 0.50 beat P3 Health Partners' score of 0.00 indicating that HeartBeam is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NYXH or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% HeartBeam N/A -1,034.04% -434.40%

HeartBeam (BEAT) Competitors

$0.51 -0.02 (-4.37%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 +0.01 (+1.62%)

As of 06:25 PM Eastern

Compare

BEAT vs. CCLD, ZEPP, OM, PIII, and NYXH

Should you buy HeartBeam stock or one of its competitors? MarketBeat compares HeartBeam with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HeartBeam include CareCloud (CCLD), Zepp Health (ZEPP), Outset Medical (OM), P3 Health Partners (PIII), and Nyxoah (NYXH). These companies are all part of the "medical info sys" industry.

How does HeartBeam compare to CareCloud?

HeartBeam (NASDAQ:BEAT) and CareCloud (NASDAQ:CCLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 681.71%. CareCloud has a consensus target price of $3.25, suggesting a potential upside of 46.40%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts clearly believe HeartBeam is more favorable than CareCloud.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
CareCloud	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

CareCloud has a net margin of 7.87% compared to HeartBeam's net margin of 0.00%. CareCloud's return on equity of 24.05% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
CareCloud	7.87%	24.05%	16.38%

CareCloud has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
CareCloud	$120.50M	0.78	$10.80M	$0.11	20.18

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 10.2% of CareCloud shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 14.8% of CareCloud shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HeartBeam has a beta of -0.82, suggesting that its stock price is 182% less volatile than the broader market. Comparatively, CareCloud has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, HeartBeam had 1 more articles in the media than CareCloud. MarketBeat recorded 2 mentions for HeartBeam and 1 mentions for CareCloud. HeartBeam's average media sentiment score of 0.50 beat CareCloud's score of 0.00 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Positive
CareCloud	Neutral

Summary

CareCloud beats HeartBeam on 9 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Zepp Health?

HeartBeam (NASDAQ:BEAT) and Zepp Health (NYSE:ZEPP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

HeartBeam has a net margin of 0.00% compared to Zepp Health's net margin of -14.70%. Zepp Health's return on equity of -15.64% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Zepp Health	-14.70%	-15.64%	-6.03%

HeartBeam has a beta of -0.82, suggesting that its stock price is 182% less volatile than the broader market. Comparatively, Zepp Health has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market.

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 52.6% of Zepp Health shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 36.0% of Zepp Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, HeartBeam and HeartBeam both had 2 articles in the media. HeartBeam's average media sentiment score of 0.50 beat Zepp Health's score of 0.27 indicating that HeartBeam is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zepp Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam currently has a consensus price target of $4.00, suggesting a potential upside of 681.71%. Zepp Health has a consensus price target of $56.28, suggesting a potential upside of 1,040.43%. Given Zepp Health's higher possible upside, analysts plainly believe Zepp Health is more favorable than HeartBeam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Zepp Health	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartBeam has higher earnings, but lower revenue than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Zepp Health	$258.90M	0.28	-$40.07M	-$2.52	N/A

Summary

HeartBeam beats Zepp Health on 8 of the 15 factors compared between the two stocks.

How does HeartBeam compare to Outset Medical?

Outset Medical (NASDAQ:OM) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

HeartBeam has lower revenue, but higher earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$119.48M	0.63	-$81.65M	-$4.16	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

7.8% of HeartBeam shares are owned by institutional investors. 2.5% of Outset Medical shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Outset Medical presently has a consensus price target of $10.00, indicating a potential upside of 147.52%. HeartBeam has a consensus price target of $4.00, indicating a potential upside of 681.71%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Outset Medical has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.82, suggesting that its share price is 182% less volatile than the broader market.

In the previous week, Outset Medical had 2 more articles in the media than HeartBeam. MarketBeat recorded 4 mentions for Outset Medical and 2 mentions for HeartBeam. Outset Medical's average media sentiment score of 1.60 beat HeartBeam's score of 0.50 indicating that Outset Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Outset Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartBeam has a net margin of 0.00% compared to Outset Medical's net margin of -63.65%. Outset Medical's return on equity of -56.13% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.65%	-56.13%	-27.45%
HeartBeam	N/A	-1,034.04%	-434.40%

Summary

HeartBeam beats Outset Medical on 10 of the 16 factors compared between the two stocks.

How does HeartBeam compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, P3 Health Partners and P3 Health Partners both had 2 articles in the media. HeartBeam's average media sentiment score of 0.50 beat P3 Health Partners' score of 0.00 indicating that HeartBeam is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

P3 Health Partners presently has a consensus price target of $14.00, indicating a potential upside of 45.53%. HeartBeam has a consensus price target of $4.00, indicating a potential upside of 681.71%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

HeartBeam has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%. P3 Health Partners' return on equity of 0.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	N/A	-19.99%
HeartBeam	N/A	-1,034.04%	-434.40%

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

P3 Health Partners has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.82, indicating that its stock price is 182% less volatile than the broader market.

HeartBeam has lower revenue, but higher earnings than P3 Health Partners. HeartBeam is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

Summary

HeartBeam beats P3 Health Partners on 10 of the 15 factors compared between the two stocks.

How does HeartBeam compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

HeartBeam has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
HeartBeam	N/A	-1,034.04%	-434.40%

Nyxoah has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.82, indicating that its share price is 182% less volatile than the broader market.

Nyxoah presently has a consensus price target of $5.96, suggesting a potential upside of 325.89%. HeartBeam has a consensus price target of $4.00, suggesting a potential upside of 681.71%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

7.8% of HeartBeam shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 18.0% of HeartBeam shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

HeartBeam has lower revenue, but higher earnings than Nyxoah. HeartBeam is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.79	-$101.92M	-$2.48	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

In the previous week, HeartBeam had 1 more articles in the media than Nyxoah. MarketBeat recorded 2 mentions for HeartBeam and 1 mentions for Nyxoah. HeartBeam's average media sentiment score of 0.50 beat Nyxoah's score of 0.00 indicating that HeartBeam is being referred to more favorably in the news media.

Company	Overall Sentiment
Nyxoah	Neutral
HeartBeam	Positive

Summary

HeartBeam beats Nyxoah on 11 of the 16 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.40M	$1.68B	$6.87B	$12.19B
Dividend Yield	N/A	N/A	2.68%	9.43%
P/E Ratio	-0.91	74.42	26.89	23.71
Price / Sales	N/A	16.34	525.46	90.71
Price / Cash	N/A	26.23	50.43	59.93
Price / Book	8.53	4.98	10.28	6.08
Net Income	-$21.01M	-$54.76M	$3.60B	$331.84M
7 Day Performance	-8.46%	-6.73%	-1.22%	-1.50%
1 Month Performance	-26.18%	-2.37%	-0.52%	-2.99%
1 Year Performance	-59.87%	-11.10%	18.97%	13.53%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	3.4972 of 5 stars	$0.51 -4.4%	$4.00 +681.7%	-58.2%	$28.40M	N/A	N/A	1,700
CCLD CareCloud	3.0054 of 5 stars	$2.21 -1.1%	$3.25 +47.4%	-12.1%	$93.69M	$120.50M	20.05	3,650
ZEPP Zepp Health	2.3471 of 5 stars	$5.49 +0.8%	$56.28 +926.1%	-58.9%	$80.52M	$271.91M	N/A	1,230
OM Outset Medical	3.8366 of 5 stars	$4.20 +1.8%	$10.00 +138.4%	-78.2%	$77.76M	$117.59M	N/A	520	News Coverage Positive News Gap Down
PIII P3 Health Partners	2.0277 of 5 stars	$10.24 +1.7%	$14.00 +36.7%	+25.8%	$74.03M	$1.46B	N/A	500	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 7/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors

BEAT vs. CCLD, ZEPP, OM, PIII, and NYXH

How does HeartBeam compare to CareCloud?

Summary

How does HeartBeam compare to Zepp Health?

Summary

How does HeartBeam compare to Outset Medical?

Summary

How does HeartBeam compare to P3 Health Partners?

Summary

How does HeartBeam compare to Nyxoah?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartBeam (BEAT) Competitors

BEAT vs. CCLD, ZEPP, OM, PIII, and NYXH

How does HeartBeam compare to CareCloud?

Do analysts prefer BEAT or CCLD?

Is BEAT or CCLD more profitable?

Which has preferable valuation & earnings, BEAT or CCLD?

Do institutionals and insiders believe in BEAT or CCLD?

Which has more volatility & risk, BEAT or CCLD?

Does the media refer more to BEAT or CCLD?

Summary

How does HeartBeam compare to Zepp Health?

Is BEAT or ZEPP more profitable?

Which has more volatility and risk, BEAT or ZEPP?

Do insiders and institutionals believe in BEAT or ZEPP?

Does the media refer more to BEAT or ZEPP?

Do analysts prefer BEAT or ZEPP?

Which has stronger valuation and earnings, BEAT or ZEPP?

Summary

How does HeartBeam compare to Outset Medical?

Which has preferable valuation and earnings, OM or BEAT?

Do institutionals and insiders believe in OM or BEAT?

Do analysts recommend OM or BEAT?

Which has more volatility and risk, OM or BEAT?

Does the media prefer OM or BEAT?

Is OM or BEAT more profitable?

Summary

How does HeartBeam compare to P3 Health Partners?

Does the media prefer PIII or BEAT?

Do analysts prefer PIII or BEAT?

Is PIII or BEAT more profitable?

Do institutionals & insiders have more ownership in PIII or BEAT?

Which has more risk & volatility, PIII or BEAT?

Which has higher earnings & valuation, PIII or BEAT?

Summary

How does HeartBeam compare to Nyxoah?

Is NYXH or BEAT more profitable?

Which has more risk and volatility, NYXH or BEAT?

Do analysts prefer NYXH or BEAT?

Do insiders and institutionals believe in NYXH or BEAT?

Which has preferable earnings & valuation, NYXH or BEAT?

Does the media prefer NYXH or BEAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools